Development of an in vivo Bioassay
Inviragen (Singapore) Pte. Ltd., formerly known as SingVax Pte. Ltd., was established in 2004 as Singapore’s first vaccine development company. SingVax focused on the development of vaccines against emerging infectious diseases that are endemic in the Asia Pacific region. Since its inception, the company has assembled a highly skilled and highly specialized team and has developed vaccine candidates to protect against hand, foot and mouth disease and Japanese encephalitis.
Using existing methodology as a starting point, BioOutsource worked with Inviragen to develop and qualify an in vivo immuno-potency assay to measure the potency of the client’s Drug Product samples.
What our clients say
"BioOutsource has proven to be a proficient outsource partner that has delivered results on time and within budget. BioOutsource's Bioweb service is a great communication tool in that we can check available data at our convenience without being hampered by the time zone differences between Singapore and the UK. Most importantly, their service oriented approach has been an extremely pleasant experience and I have never met a more amenable group of people to work with. I can only give them my highest recommendation."
CEO Inviragen (Singapore)